Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
RESEARCH TRIANGLE PARK, N.C., March 29, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that it will present preclinical data on trilaciclib,...
-
Phase 2 trial of trilaciclib in triple-negative breast cancerPhase 1b/2a trial of G1T38 in estrogen receptor-positive breast cancer Oral SERD (G1T48) in IND-enabling studies; Phase 1 trial planned for...
-
RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that Chief Executive Officer Mark Velleca, MD, PhD, will...
-
RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2016 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. a clinical-stage oncology company, announced today a clinical trial collaboration with Genentech, a member of...
-
RESEARCH TRIANGLE PARK, N.C., Nov. 21, 2016 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that preliminary clinical data from its lead CDK4/6...
-
RESEARCH TRIANGLE PARK, N.C., Aug. 10, 2016 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that Chief Medical Officer Raj Malik, MD, will present a...
-
Proceeds will advance lead CDK4/6 inhibitors through early and mid-stage clinical trials, expand pipeline in multiple oncology indications RESEARCH TRIANGLE PARK, N.C., May 11, 2016 (GLOBE...
-
Preliminary clinical data on G1T28 in combination with chemotherapy in newly diagnosed small-cell lung cancer patientsPreclinical data on potential best-in-class oral CDK4/6 inhibitor G1T38 RESEARCH...
-
RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2016 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that Chief Executive Officer Mark Velleca, MD,...
-
RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2015 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that Chief Executive Officer Mark Velleca, MD, PhD, will...